FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer

Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population

DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial

DiaMedica said it plans to launch the trial later in 2026

SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients

The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations

Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial

The company announced positive topline data from the Phase II ZUPREME-1 trial

Rapid medical weight loss fuels surge in facial aesthetics, Allergan data shows

Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients

This study evaluated a difficult-to-treat Crohn's disease patient population

Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer

KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients

Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe

AA, a chronic immune disease, can cause extensive and unpredictable hair loss